{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:50:20Z","timestamp":1784119820240,"version":"3.55.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.ctrv.2016.05.003","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:45:24Z","timestamp":1463532324000},"page":"32-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus"],"prefix":"10.1016","volume":"47","author":[{"given":"Simron","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia L.","family":"Asa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Dey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagen","family":"Kennecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Laidley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Asmis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shereen","family":"Ezzat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Mete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Pasieka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Segelov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.05.003_b0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2016.05.003_b0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10555-011-9292-1","article-title":"Current knowledge on diagnosis and staging of neuroendocrine tumors","volume":"30","author":"Oberg","year":"2011","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.ctrv.2016.05.003_b0015","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0020","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/j.1572-0241.2007.01185.x","article-title":"A three-decade analysis of 3911 small intestinal neuroendocrine tumors: the rapid pace of no progress","volume":"102","author":"Modlin","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpg.2013.01.006","article-title":"Epidemiology of gastroenteropancreatic neuroendocrine tumours","volume":"26","author":"Fraenkel","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0030","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0040","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3747\/co.v17i3.484","article-title":"Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian national expert group","volume":"17","author":"Kocha","year":"2010","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0045","doi-asserted-by":"crossref","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","article-title":"Neuroendocrine tumors, version 1.2015","volume":"13","author":"Kulke","year":"2015","journal-title":"J Natl Compr Cancer Networks"},{"key":"10.1016\/j.ctrv.2016.05.003_b0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.ctrv.2016.05.003_b0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000335600","article-title":"ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update","volume":"95","author":"Salazar","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0060","series-title":"Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy: The phase 3 TELESTAR clinical trial","author":"Kulke","year":"2015"},{"key":"10.1016\/j.ctrv.2016.05.003_b0065","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.05.003_b0070","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.05.003_b0075","series-title":"177Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1 trial","author":"Strosberg","year":"2015"},{"key":"10.1016\/j.ctrv.2016.05.003_b0080","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.05.003_b0085","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1245\/s10434-014-4145-0","article-title":"Consensus recommendations for the diagnosis and management of pancreatic neuroendocrine tumors: guidelines from a canadian national expert group","volume":"22","author":"Singh","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0090","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/jca.4502","article-title":"Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis","volume":"3","author":"Tsikitis","year":"2012","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2016.05.003_b0095","first-page":"817","article-title":"Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study","volume":"35","author":"Faggiano","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 7","key":"10.1016\/j.ctrv.2016.05.003_b0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mds295","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0110","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.05.003_b0115","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid\u2013a comprehensive review","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0120","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ctrv.2016.05.003_b0125","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ctrv.2016.05.003_b0130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/PAS.0b013e3181ce1447","article-title":"Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set","volume":"34","author":"Klimstra","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12022-015-9379-2","article-title":"Comparison of three Ki-67 index quantification methods and clinical significance in pancreatic neuroendocrine tumors","volume":"26","author":"Kroneman","year":"2015","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00428-013-1408-2","article-title":"Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids","volume":"462","author":"Warth","year":"2013","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2016.05.003_b0145","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/PAS.0b013e318263207c","article-title":"Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods","volume":"36","author":"Tang","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/PAS.0b013e31824aba59","article-title":"PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms","volume":"36","author":"Chan","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0155","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/PAS.0b013e31826f042c","article-title":"Islet-1 is a sensitive but not entirely specific marker for pancreatic neuroendocrine neoplasms and their metastases","volume":"37","author":"Graham","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0160","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1097\/PAS.0b013e31818d7d8b","article-title":"Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors","volume":"33","author":"Srivastava","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPA.0b013e3181ebaffd","article-title":"NANETS consensus guidelines for the diagnosis of neuroendocrine tumor","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2016.05.003_b0170","first-page":"113","article-title":"Diagnostic approach to neuroendocrine neoplasms of the gastrointestinal tract and pancreas","volume":"31","author":"Uccella","year":"2015","journal-title":"Turk Patoloji Derg"},{"key":"10.1016\/j.ctrv.2016.05.003_b0175","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/PAS.0000000000000400","article-title":"Non-L-cell immunophenotype and large tumor size in rectal neuroendocrine tumors are associated with aggressive clinical behavior and worse prognosis","volume":"39","author":"Kim","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0180","doi-asserted-by":"crossref","first-page":"13240","DOI":"10.3748\/wjg.v21.i47.13240","article-title":"Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours","volume":"21","author":"Tsolakis","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0185","article-title":"World health organization, international agency for research on cancer","author":"Bosman","year":"2010"},{"key":"10.1016\/j.ctrv.2016.05.003_b0190","series-title":"AJCC cancer staging manual","year":"2010"},{"key":"10.1016\/j.ctrv.2016.05.003_b0195","unstructured":"College of American Pathologists \u2013 Cancer Biomarker Reporting Templates. http:\/\/www.cap.org\/web\/oracle\/webcenter\/portalapp\/pagehierarchy\/cancer_protocol_templates.jspx?_adf.ctrl-state=58em7c6lb_124&_afrLoop=415532164792013#!; [accessed 21.01.2016]."},{"key":"10.1016\/j.ctrv.2016.05.003_b0200","article-title":"Four neuroendocrine tumor types and the neuroendocrine carcinoma of the duodenum. Analysis of 203 cases","author":"Vanoli","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0205","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1158\/1078-0432.CCR-15-0548","article-title":"Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas","volume":"22","author":"Tang","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.05.003_b0210","article-title":"The clinicopathologic heterogeneity of grade 3 gastroenteropancreatic neuroendocrine neoplasms: morphological differentiation and proliferation identify different prognostic categories","author":"Milione","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0215","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.semdp.2013.06.005","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: historical context and current issues","volume":"30","author":"Yang","year":"2013","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0220","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0225","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2016.05.003_b0235","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2214\/AJR.12.9758","article-title":"Imaging features of carcinoid tumors of the gastrointestinal tract","volume":"201","author":"Ganeshan","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0240","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1016\/j.ejrad.2011.11.007","article-title":"Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI","volume":"81","author":"Giesel","year":"2012","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0245","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging","volume":"23","author":"Dromain","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0250","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s12020-012-9631-1","article-title":"Diagnostic performance of Gallium-68 somatostatin receptor PET and PET\/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis","volume":"42","author":"Treglia","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.ctrv.2016.05.003_b0255","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2003.01885.x","article-title":"SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours","volume":"59","author":"Krausz","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ctrv.2016.05.003_b0260","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/MNM.0000000000000239","article-title":"Contribution of 111In-pentetreotide SPECT\/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours","volume":"36","author":"Sainz-Esteban","year":"2015","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ctrv.2016.05.003_b0265","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2214\/AJR.09.2760","article-title":"Value of CT enteroclysis in suspected small-bowel carcinoid tumors","volume":"194","author":"Kamaoui","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0270","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1148\/radiol.11110143","article-title":"Prospective blinded comparison of wireless capsule endoscopy and multiphase CT enterography in obscure gastrointestinal bleeding","volume":"260","author":"Huprich","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0275","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1148\/radiol.2513081819","article-title":"Small-bowel neoplasms: prospective evaluation of MR enteroclysis","volume":"251","author":"Masselli","year":"2009","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0280","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1148\/radiol.09090828","article-title":"MR enteroclysis in the diagnosis of small-bowel neoplasms","volume":"254","author":"Van Weyenberg","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335595","article-title":"ENETS consensus guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle Fave","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0290","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0295","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000335594","article-title":"ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms","volume":"95","author":"Caplin","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0300","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ctrv.2016.05.003_b0305","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1677\/ERC-08-0247","article-title":"Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience","volume":"16","author":"Scigliano","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ctrv.2016.05.003_b0310","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","article-title":"Neuroendocrine hepatic metastases: does aggressive management improve survival?","volume":"241","author":"Touzios","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2016.05.003_b0315","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0320","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1245\/s10434-011-1832-y","article-title":"Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis","volume":"18","author":"Mayo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jamcollsurg.2012.08.027","article-title":"Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies","volume":"216","author":"Mayo","year":"2013","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ctrv.2016.05.003_b0330","doi-asserted-by":"crossref","first-page":"471203","DOI":"10.1155\/2012\/471203","article-title":"Hepatic arterial embolization for the treatment of metastatic neuroendocrine tumors","volume":"2012","author":"Lee","year":"2012","journal-title":"Int J Hepatol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0335","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/bjs.6587","article-title":"Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome","volume":"96","author":"Sward","year":"2009","journal-title":"Br J Surg"},{"key":"10.1016\/j.ctrv.2016.05.003_b0340","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","article-title":"Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver","volume":"18","author":"Ruutiainen","year":"2007","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0345","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.ejca.2013.05.012","article-title":"Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study","volume":"49","author":"Benson","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2016.05.003_b0350","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.2967\/jnumed.113.135855","article-title":"The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis","volume":"55","author":"Devcic","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2016.05.003_b0355","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1634\/theoncologist.2012-0434","article-title":"Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned","volume":"18","author":"Yao","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2016.05.003_b0360","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/S1470-2045(14)70375-4","article-title":"Outcomes and endpoints in trials of cancer treatment: the past, present, and future","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0365","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S1499-3872(15)60344-7","article-title":"Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials","volume":"14","author":"Petrelli","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.ctrv.2016.05.003_b0370","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0375","article-title":"Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results on long term survival","author":"Rinke","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ctrv.2016.05.003_b0380","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the spanish task force group for neuroendocrine tumors (GETNE) dagger","volume":"26","author":"Grande","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0385","series-title":"SWOG S0518: Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab in advanced, poor prognosis carcinoid patients","author":"Yao","year":"2015"},{"key":"10.1016\/j.ctrv.2016.05.003_b0390","series-title":"Everolimus in advanced, non-functional neuroendocrine tumors of lung or gastrointestinal origin: efficacy and safety results from the placebo-controlled, double-blind, multicenter, phase 3 RADIANT-4 study","author":"Yao","year":"2015"},{"key":"10.1016\/j.ctrv.2016.05.003_b0395","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-011-2039-y","article-title":"Lutetium-labelled peptides for therapy of neuroendocrine tumours","volume":"39","author":"Kam","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2016.05.003_b0400","first-page":"62s","article-title":"Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs","volume":"46","author":"Kwekkeboom","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2016.05.003_b0405","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1002\/cncr.26616","article-title":"Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide","volume":"118","author":"Savelli","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.05.003_b0410","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2016.05.003_b0415","first-page":"83s","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctrv.2016.05.003_b0420","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bpg.2013.01.004","article-title":"Peptide receptor radionuclide therapy (PRRT) for GEP-NETs","volume":"26","author":"Bergsma","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0425","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0430","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.ctrv.2016.05.003_b0435","article-title":"ELECT: a phase 3 study of efficacy and safety of lanreotide autogel\/depot (LAN) treatment for carcinoid syndrome in patients with neuroendocrine tumors (NETs)","volume":"32","author":"Vinik","year":"2014","journal-title":"J Clin Oncol"},{"issue":"395","key":"10.1016\/j.ctrv.2016.05.003_b0440","article-title":"1135PD quality of life (QOL) associated with lanreotide autogel (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumour (GEPNET) patients: results of the elect study","volume":"25","author":"Gomez-Panzani","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2016.05.003_b0445","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review","volume":"62","author":"Oberg","year":"2000","journal-title":"Digestion"},{"key":"10.1016\/j.ctrv.2016.05.003_b0450","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0455","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.05.003_b0460","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1634\/theoncologist.2014-0120","article-title":"Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study","volume":"19","author":"Strosberg","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2016.05.003_b0465","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/cam4.435","article-title":"Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors","volume":"4","author":"Al-Efraij","year":"2015","journal-title":"Cancer Med"},{"issue":"935\u2013942","key":"10.1016\/j.ctrv.2016.05.003_b0470","first-page":"e931","article-title":"Radiofrequency ablation for neuroendocrine liver metastases: a systematic review","volume":"26","author":"Mohan","year":"2015","journal-title":"J Vasc Interv Radiol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216300214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T02:15:22Z","timestamp":1668651322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216300214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":94,"alternative-id":["S0305737216300214"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.05.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}